Baillie Gifford Global Discovery Fund B Accumulation

Baillie Gifford Global Discovery Fund B Accumulation
Baillie Gifford & Co Limited.
Open Ended Investment Company
0.78 %
Risk Rating
3 Year Sharpe
3 Year Alpha
0 %
S&P Global Small TR USD
The Fund aims to outperform (after deduction of costs) the S&P Global Small Cap Index, as stated in Sterling, by at least 2% per annum over rolling five-year periods.The Fund will invest at least 90% in shares of companies. The Fund will be actively managed and will invest in shares of companies in any country and in any sector which typically at the time of initial purchase have a market capitalisation of US$5 billion or less and that the ACD considers will offer excellent future growth prospects.
Holding %
Alnylam Pharmaceuticals Inc 5.88 %
Teladoc Health Inc 5.18 %
MarketAxess Holdings Inc 4.68 %
Ocado Group PLC 4.59 %
Chegg Inc 3.62 %
Tesla Inc 3.33 %
Zillow Group Inc C 3.11 %
NovoCure Ltd 2.95 %
LendingTree Inc 2.53 %
Genmab A/S 2.34 %
Region %
United States 67.31 %
United Kingdom 11.20 %
Asia - Emerging 5.15 %
Sector %
Healthcare 42.99 %
Technology 20.26 %
Financial Services 8.59 %
Consumer Defensive 8.44 %
Consumer Cyclical 8.26 %
Communication Services 5.58 %
Industrials 5.55 %
Baillie Gifford & Co Limited.
EH1 3AN, Edinburgh, United Kingdom
Legal Structure
Open Ended Investment Company


Luke Ward
Joined 01/01/2018

Luke graduated MEng (Hons) in Mechanical Engineering from the University of Edinburgh in 2012. Luke joined Baillie Gifford in 2012 and is an Investment Manager in the Global Discovery Team. Luke is also a Deputy Manager.

Svetlana Viteva
Joined 01/01/2018

Svetlana graduated BA in Economics and BA in Business Administration from the American University in Bulgaria in 2008, MSc in Investment Analysis from Stirling University in 2009 and PhD in Accounting and Finance from Stirling University in 2012. Svetlana joined Baillie Gifford in 2012 and is an Investment Manager in the Global Discovery Team. Svetlana is also a Deputy Manager. She is a CFA Charterholder.

Douglas Brodie
Joined 05/03/2011

Douglas graduated BSc in Molecular Biology & Biochemistry from Durham University in 1997 and with a DPhil in Molecular Immunology from the University of Oxford in 2001. He joined Baillie Gifford in 2001 and is Head of the Global Discovery Team. Douglas became a Partner in 2015 is a CFA Charterholder.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.